Aktie A2PSPW INNOCAN PHARMA CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen InnoCan Pharma Corporation

Aktien

A2PSPW

CA45783P1027

INNO

Pharmazeutika

Markt geschlossen - Canadian Securities Exchange
Andere Börsenplätze
 15:31:13 06.12.2024 		% 5 Tage % 1. Jan.
0,2150 CAD 0,00 % Intraday Chart für InnoCan Pharma Corporation -6,52 % -30,65 %
26.11. InnoCan Pharma veröffentlicht ermutigende Ergebnisse der Studie mit LPT-CBD an Minischweinen MT
26.11. Innocan Pharma Corporation gibt ermutigende Ergebnisse einer Studie zur Sicherheitsbewertung von LPT-CBD an Minischweinen bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
InnoCan Pharma Releases Encouraging Results from Study of LPT-CBD on Minipigs
26.11.
Innocan Pharma Corporation Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs
26.11.
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs
26.11.
InnoCan Pharma : MD&A Report for Three & Nine month period ended September 30, 2024
21.11.
InnoCan Pharma : Financial Statements as of September 30, 2024
21.11.
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
20.11.
InnoCan Pharma Swings to a Q3 Profit on Revenue Gains
20.11.
Innocan Pharma Reports Third Quarter 2024 Financial Results
20.11.
Innocan Pharma to Present at the 2024 ThinkEquity Conference
21.10.
Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience
16.10.
Innocan Pharma's LPT-CBD Shows Success in Relieving Osteoarthritis Pain in Dogs
11.10.
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
11.10.
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
11.10.
Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide
09.10.
Innocan Says FDA "Positive" on it Liposomal Technology-CBD Drug
03.09.
Innocan Pharma Corporation Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting
03.09.
Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting
03.09.
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
29.08.
InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding
29.08.
Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration
22.08.
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding
22.08.
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
12.08.
Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over 2.8X to $8.6 Million
12.08.
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
29.07.
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
26.07.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PSPW Aktie
  4. Nachrichten InnoCan Pharma Corporation
  5. Andere Sprachen
Vereinigte Staaten

MarketScreener is also available in this country: United States.

Switch edition
Bei der aktuellen länderspezifischen Edition bleiben